Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population.
Journal
Case reports in infectious diseases
ISSN: 2090-6625
Titre abrégé: Case Rep Infect Dis
Pays: Egypt
ID NLM: 101573243
Informations de publication
Date de publication:
2024
2024
Historique:
received:
11
12
2023
revised:
14
05
2024
accepted:
24
05
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
epublish
Résumé
AZD7442 (150 mg of tixagevimab plus 150 mg of cilgavimab) has been approved for the preexposure prophylaxis of COVID-19 and for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of severe COVID-19. Thus, the aim of the present study is to evaluate the neutralizing capacity of tixagevimab and cilgavimab across different SARS-CoV-2 variants in two patients who received AZD7442 for immunoprophylaxis. A cohort of subjects (
Identifiants
pubmed: 39246664
doi: 10.1155/2024/9163490
pmc: PMC11380708
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
9163490Informations de copyright
Copyright © 2024 Constant Gillot et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.